KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $114.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 4.0% year-over-year to $114.0 million, compared with a TTM value of $114.0 million through Dec 2025, down 4.0%, and an annual FY2025 reading of $114.0 million, down 4.0% over the prior year.
  • Non-Current Deffered Revenue was $114.0 million for Q4 2025 at Recursion Pharmaceuticals, up from $111.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $129.6 million in Q1 2025 and bottomed at $2.8 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $57.2 million, with a median of $51.2 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue surged 1609.51% in 2022, then plummeted 69.42% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $4.1 million in 2021, then soared by 1609.51% to $70.3 million in 2022, then decreased by 27.07% to $51.2 million in 2023, then surged by 131.79% to $118.8 million in 2024, then fell by 4.0% to $114.0 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for RXRX at $114.0 million in Q4 2025, $111.2 million in Q3 2025, and $126.2 million in Q2 2025.